Cat. No. 4554
Chemical Name: 2-[4-[[4-Hydroxy-3-(1-methylethyl)p
Biological ActivityThyromimetic; high affinity agonist at thyroid hormone receptor (TR) β and TRα receptors (KD values are 67 and 440 pM respectively). Displays 5- and 100-fold greater potency than the endogenous agonist T3 in vitro at TRα1 and TRβ1 receptors respectively. Promotes reverse cholesterol transport in chow- and fat-fed mice. Induces proliferation of hepatocytes and pancreatic acinar cells in rats independent of prior tissue injury.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Columbano et al (2006) The thyroid hormone receptor-β agonist GC-1 induces cell proliferation in rat liver and pancreas. Endocrinology 147 3211. PMID: 16574785.
Johansson et al (2005) Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc.Natl.Acad.Sci. U S A 102 10297. PMID: 16006512.
Chiellini et al (1998) A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem.Biol. 5 299. PMID: 9653548.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses GC 1 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: GC 1, supplier, GC1, thryomimetic, high, affinity, thyroid, hormone, receptor, TR, TRalpha, TRbeta, agonists, T3, reverse, cholesterol, transport, hypercholesterolaemia, cellular, proliferation, Tocris Bioscience, Other Nuclear Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Synthetic retinoid; induces differentiation of stem cellsSI-2 hydrochloride
Steroid receptor coactivator 3 (SRC-3) inhibitorSR 0987
T cell-specific RORγ (RORγt) agonistWAY 252623
Potent LXR agonist
April 1 - 5, 2017
Washington, D.C., USA